Catalog No.:AA01B247

1380650-53-2 | sodium 1-(4-{4-[3-methyl-4-({[(1R)-1-phenylethoxy]carbonyl}amino)-1,2-oxazol-5-yl]phenyl}phenyl)cyclopropane-1-carboxylate

Name: Name:sodium 1-(4-{4-[3-methyl-4-({[(1R)-1-phenylethoxy]carbonyl}amino)-1,2-oxazol-5-yl]phenyl}phenyl)cyclopropane-1-carboxylate
Brand: AABLOCKS
SKU: AA01B247
Availability: InStock
Rating: 90 (10 reviews)

Pack Size

Purity

Availability

Price(USD)

Quantity

1mg

98%

1 week

$146.00 $102.00

- +

5mg

98%

1 week

$201.00 $141.00

- +

10mg

98%

1 week

$289.00 $202.00

- +

50mg

98%

1 week

$765.00 $535.00

- +

100mg

98%

1 week

$1,241.00 $869.00

- +

Technical Information
Properties
Literature
Request for Quotation
Download SDS

Technical Information
Properties
Literature

Technical Information

Catalog Number:

AA01B247

Chemical Name:

sodium 1-(4-{4-[3-methyl-4-({[(1R)-1-phenylethoxy]carbonyl}amino)-1,2-oxazol-5-yl]phenyl}phenyl)cyclopropane-1-carboxylate

CAS Number:

1380650-53-2

Molecular Formula:

C29H25N2NaO5

Molecular Weight:

504.5090

MDL Number:

MFCD30749917

SMILES:

O=C(O[C@@H](c1ccccc1)C)Nc1c(C)noc1c1ccc(cc1)c1ccc(cc1)C1(CC1)C(=O)[O-].[Na+]

Properties

Literature

Title: Kihara Y, et al. Lysophospholipid receptors in drug discovery. Exp Cell Res. 2015 May 1;333(2):171-7.

Title: Glenn Rosen, et al. LPA1 antagonists BMS-986020 and BMS-986234 for idiopathic pulmonary fibrosis: Preclinical evaluation of hepatobiliary homeostasis. European Respiratory Journal.

Title: Palmer SM, et al. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. Chest. 2018 Nov;154(5):1061-1069.

Title: Adrienne Pena, et al. Autoradiographic evaluation of 8FBMT-083133, a lysophosphatidic acid receptor 1 (LPA1) radioligand. The jornal of nuclear medicine.

Quotation Request

Company Name:

Contact Person:

Email:

Quantity Required:

Country:

Additional Info:

SDS